Where is aromatase made

In addition, they can have excessive weight gain and a fatty liver. Women who are pregnant with fetuses that have aromatase deficiency often experience mild symptoms of the disorder even though they themselves do not have the disorder. These women may develop hirsutism, acne, an enlarged clitoris clitoromegaly , and a deep voice. These features can appear as early as 12 weeks of pregnancy and go away soon after delivery. The prevalence of aromatase deficiency is unknown; approximately 20 cases have been described in the medical literature.

Mutations in the CYP19A1 gene cause aromatase deficiency. The CYP19A1 gene provides instructions for making an enzyme called aromatase.

This enzyme converts a class of hormones called androgens, which are involved in male sexual development, to different forms of estrogen. In females, estrogen guides female sexual development before birth and during puberty. In both males and females, estrogen plays a role in regulating bone growth and blood sugar levels. During fetal development, aromatase converts androgens to estrogens in the placenta, which is the link between the mother's blood supply and the fetus.

This conversion in the placenta prevents androgens from directing sexual development in female fetuses. After birth, the conversion of androgens to estrogens takes place in multiple tissues. CYP19A1 gene mutations that cause aromatase deficiency decrease or eliminate aromatase activity. A shortage of functional aromatase results in an inability to convert androgens to estrogens before birth and throughout life. As a result, there is a decrease in estrogen production and an increase in the levels of androgens, including testosterone.

In affected individuals, these abnormal hormone levels lead to impaired female sexual development, unusual bone growth, insulin resistance, and other signs and symptoms of aromatase deficiency. Several clinical disorders compromise predicted adult height, including GH deficiency, the McCune-Albright syndrome, familial male-limited precocious puberty, congenital adrenal hyperplasia, constitutional delay of puberty, and idiopathic short statue.

Aromatase inhibitors have been used in each of these disorders, and early results are promising , Notably, the groups of Leo Dunkel and Nelly Mauras , have led the way in performing extensive clinical studies to enhance overall stature in adolescents with various forms of short stature and have critically analyzed their data. Several families have been described in which both males and females exhibit increased aromatase activity and high estrogen levels with an autosomal dominant form of inheritance 10 , — Later families were described by a group headed by Constantine Stratakis and by Masashi Demura, a colleague of Serdar Bulun, who conducted careful genetic studies to reveal that regional rearrangements in chromosome 15Q21 cause formation of cryptic promoters for the aromatase gene resulting in aromatase overexpression Clinical features in males include pre- or peripubertal gynecomastia, hypogonadotropic hypogonadism, and compromised final height in association with high circulating estrogen levels.

Hypogonadism results from the negative feedback effects of estradiol to suppress gonadotropins, but this depends on the level of severity of the aromatase deficiency. In women, the features include precocious thelarche, macromastia, enlarged uterus, and menstrual irregularities. Second-generation aromatase inhibitors have been useful in the treatment of these patients The group of Melvin Grumbach in collaboration with Akira Morishima, Felix Conte, and Evan Simpson described the first cases of aromatase deficiency Now reported in seven males and 10 females , , this condition prevents the placenta from metabolizing androgens to estrogens, and the female fetuses are exposed to excessive androgen levels in utero resulting in androgenization of the female fetus and virilization of the mother during pregnancy.

Phenotypic features in girls include clitoromegaly, scrotalization of labioscrotal folds, and occasionally a urogenital sinus. At puberty, the girls have hypergonadotropic hypogonadism, lack of breast development, primary amenorrhea, and progressive virilization. At this time, all reported females with aromatase deficiency have been placed on estrogen replacement at the time of puberty, so there are no data as to the progression of the condition into adulthood, unlike the situation in men see Section XIV.

Comparison of the phenotypes of aromatase-deficient and normal males, both in mice and in men, provides compelling information regarding the role of estrogens in the male. As shown in Table 2 , aromatase deficiency exerts major effects on liver function, carbohydrate metabolism, insulin sensitivity, adiposity, plasma lipids, bone, and sexual behavior.

Derived from Ref. As discussed in Section III. These hormones then act directly in the cells of synthesis autocrine or intracrine function , in the cells nearby paracrine function , in the cells next to the site of synthesis juxtacrine function , or in neurons themselves neurocrine function. Physiological studies of aromatase provided compelling examples of each of these types of action.

For example, in the brain, estradiol synthesized locally via aromatase exerts autocrine, paracrine, juxtacrine, and neurocrine effects In the postmenopausal breast, local synthesis may also be the predominant determinant of tissue estrogen levels The importance of aromatase has increased as our understanding of the scope of estrogen action has widened.

With the recognition of molecular defects in the ER and in aromatase expression, we now know that estrogen subserves multiple functions in males as well as in females. Thus, aromatase is important in brain function, bone metabolism, the metabolic syndrome, energy expenditure, cardiovascular physiology, testis and prostate physiology, and regulation of gonadotropin secretion in the male. The production of estradiol by aromatase in extraglandular tissues in postmenopausal women provides a compelling example of the role of autocrine, paracrine, and intracrine mechanisms.

The story of the evolution of our understanding of these multiple roles for aromatase represents an odyssey driven primarily by allowing observational data to generate new hypotheses. The history of aromatase outlines a success story where identification of a molecular target and inhibitors of it have led to substantially improved therapies for women with breast cancer.

Several aspects of this success story such as the role of serendipity, mentoring, critical masses of investigators, key workshop meetings, molecular biology technical advances, pharmaceutical support, and fruitful collaborations among investigators provide a roadmap for advances in other areas. Disclosure Summary: E. A photograph of each individual identified within text by an asterisk appears online on the Aromatase History Web Site www. J Biol Chem 91 : — Google Scholar.

J Biol Chem 87 : — Die Naturwissenschaften 17 : Butenandt A Uber die chemische untersuchung der sexualhormone. Zeitschrift fur Angewandte Chemie 44 : — Baltimore, MD; Waverly Press. Endocr Rev 26 : — J Clin Endocrinol Metab 87 : — Santen RJ Feedback control of luteinizing hormone and follicle-stimulating hormone secretion by testosterone and estradiol in men: physiological and clinical implications. Clin Biochem 14 : — J Steroid Biochem Mol Biol 95 : 63 — J Clin Invest 60 : — Bernard C An introduction to the study of experimental medicine.

Doubt in experimental reasoning. Classics of medicine library. Zondek B Oestrogenic hormone in the urine of the stallion. Nature : Steinach E , Kun H Transformation of male sex hormones into a substance with the action of a female hormone. Lancet : Biochim Biophys Acta 17 : — Acta Endocrinol 18 : — Ryan KJ Biological aromatization of steroids.

J Biol Chem : — Gut M Some aspects of stereoselectivity in the introduction of tritium into steroids. Washington DC : Plenum Press.

The development of inhibitors of the enzyme system in human placenta. Endocrinology 92 : — Endocrinology 71 : — Biochem Biophys Res Commun 6 : — Thompson Jr EA , Siiteri PK Utilization of oxygen and reduced nicotinamide adenine dinucleotide phosphate by human placental microsomes during aromatization of androstenedione. Biochemistry 8 : — Steroids 50 : — Protein Science 4 : — Mol Endocrinol 21 : — Lieberman S , Ma S , He Y New assumptions about oxidative processes involved in steroid hormone biosynthesis: is the role of cytochrome Pactivated dioxygen limited to hydroxylation reactions or are dioxygen insertion reactions also possible?

J Steroid Biochem Mol Biol 94 : — Nature : — J Am Chem Soc 84 : — The stereochemistry of aromatization of C19 and C18 steroids. Biochemistry 7 : 33 — Horm Res 11 : — Synthesis and biological activity of androstenedione derivatives.

J Med Chem 28 : — J Steroid Biochem Mol Biol 37 : — Steroids 39 : — The stereochemistry of hydrogen elimination at C-2 during aromatization. J Am Chem Soc 91 : — The stereochemistry of hydrogen elimination of C-2 during aromatization. Chakraborty J , Hopkins R , Parke DV Inhibition studies on the aromatization of androstene-3,dione by human placental microsomal preparations. Biochem J : 19 P—20P. Jordan VC , Brodie AM Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer.

Steroids 72 : 7 — J Reprod Fertil 13 : — Harper MJ , Walpole AL Contrasting endocrine activities of cis and trans isomers in a series of substituted triphenylethylenes. J Clin Endocrinol Metab 49 : — J Clin Endocrinol Metab 36 : — J Clin Endocrinol Metab 27 : — Steroids 8 : — J Steroid Biochem 6 : — J Clin Endocrinol Metab 26 : — Siiteri PK , The origin of placental estrogen during human pregnancy. In: MacDonald PC, ed.

Ann NY Acad Sci : — J Clin Endocrinol Metab 35 : — Br J Cancer 31 : — Steroids 33 : — Cancer Res 42 8 Suppl : s — s. J Clin Endocrinol Metab 57 : — Cancer 70 : — Endocrinology : — J Clin Endocrinol Metab 79 : — Cancer Res 58 : — J Clin Endocrinol Metab 81 : — Biomed Pharmacother 57 : — J Steroid Biochem Mol Biol 79 : 93 — J Steroid Biochem Mol Biol 95 : 35 — J Clin Endocrinol Metab 85 : — Cancer Res 67 : — J Steroid Biochem Mol Biol 67 : — Cancer Res 56 : — Geisler J Breast cancer tissue estrogens and their manipulation with aromatase inhibitors and inactivators.

J Steroid Biochem Mol Biol 86 : — J Clin Endocrinol Metab 90 : — J Steroid Biochem Mol Biol 81 : 57 — Eur J Cancer Clin Oncol 22 : — Brueggemeier RW Overview of the pharmacology of the aromatase inactivator exemestane.

Breast Cancer Res Treat 74 : — Epidemiology 7 : — J Steroid Biochem Mol Biol 72 : 23 — J Clin Endocrinol Metab 59 : 29 — Masamura S , Santner SJ , Santen RJ Evidence of in situ estrogen synthesis in nitrosomethylurea-induced rat mammary tumors via the enzyme estrone sulfatase. J Steroid Biochem Mol Biol 58 : — Biochemistry 15 : — J Med Chem 21 : — Henderson D , Norbisrath G , Kerb U 1-Methyl-1,4-androstadiene-3,dione SH : characterization of an irreversible inhibitor of estrogen biosynthesis.

J Steroid Biochem 24 : — Implications for the structure of the active site. Steroids 45 : — J Med Chem 35 : — J Steroid Biochem Mol Biol 44 : — Brueggemeier RW Aromatase inhibitors—mechanisms of steroidal inhibitors. Breast Cancer Res Treat 30 : 31 — Steroids 38 : — Biochem Biophys Res Commun : — Mechanism-based enzyme-activated irreversible inhibitors of estrogen biosynthesis.

Favia AD , Cavalli A , Masetti M , Carotti A , Recanatini M Three-dimensional model of the human aromatase enzyme and density functional parameterization of the iron-containing protoporphyrin IX for a molecular dynamics study of heme-cysteinato cytochromes. Proteins 62 : — Brodie AM , Longcope C Inhibition of peripheral aromatization by aromatase inhibitors, 4-hydroxy- and 4-acetoxy-androstene-3,dione.

Endocrinology : 19 — Beatson GT On the treatment of inoperable cases of carcinoma of the mamma. Suggestions for a new method of treatment with illustrative cases. Lancet II : — Endocr Rev 11 : — Postgrad Med 21 : — Cancer 10 : — Trans Assoc Am Physicians 90 : — Cancer 16 : — Report of the Cooperative Breast Cancer Group.

JAMA : — Cancer 32 : 31 — Cancer 39 : — Role of altered drug metabolism. Santen RJ Suppression of estrogens with aminoglutethimide and hydrocortisone medical adrenalectomy as treatment of advanced breast carcinoma: a review.

Breast Cancer Res Treat 1 : — J Clin Endocrinol Metab 47 : — J Clin Oncol 19 : — Lonning PE Oestrogen suppression—lessons from clinical studies. Rose C A comparison of the efficacy of aromatase inhibitors in second-line treatment of metastatic breast cancer.

Mokbel K The evolving role of aromatase inhibitors in breast cancer. Int J Clin Oncol 7 : — Bull Cancer 87 Spec No. Reddy P A review of the newer aromatase inhibitors in the management of metastatic breast cancer. J Clin Pharm Ther 23 : 81 — Cocconi G First generation aromatase inhibitors—aminoglutethimide and testololactone.

Breast Cancer Res Treat 30 : 57 — Breast Cancer Res Treat 30 : 81 — Breast Cancer Res Treat 23 : 7 — Samojlik E , Santen RJ , Worgul TJ Plasma estrone-sulfate: assessment of reduced estrogen production during treatment of metastatic breast carcinoma. Cancer 43 : — N Engl J Med : — J Clin Endocrinol Metab 51 : — Cancer 73 : — Cancer Res 42 8 Suppl : s.

Lancet 1 : — Br J Cancer 47 : — Harris AL , Dowsett M , Smith IE , Jeffcoate S Hydrocortisone alone vs hydrocortisone plus aminoglutethimide: a comparison of the endocrine effects in postmenopausal breast cancer.

Eur J Cancer Clin Oncol 20 : — Clin Endocrinol Oxf 22 : — Samojlik E , Santen RJ Potency of the effect of D-stereoisomer of aminoglutethimide on adrenal and extraadrenal steroidogenesis.

Lancet 2 : — Oncogene 21 : — Cancer Res 47 : — Cancer Res 49 : — Identification of the glucuronide as a major urinary metabolite in patients and biliary metabolite in the rat. Ann Oncol 5 Suppl 7 : S19 — S J Steroid Biochem Mol Biol 95 : 75 — J Clin Endocrinol Metab 70 : — J Clin Endocrinol Metab 74 : — Breast Cancer Res Treat 30 : 95 — Ann Oncol 14 : 62 — Jordan VC Laboratory models of breast cancer to aid the elucidation of antiestrogen action.

J Lab Clin Med : — Cancer Metastasis Rev 7 : — Clinical Cancer Research 6 : — J Natl Cancer Inst 87 : — Cancer Res 54 : — Cancer Res 50 : — Cancer Res 55 : — Breast Cancer Res Treat 50 : 63 — Breast Cancer Res Treat 57 : — Cancer Res 65 : — J Natl Cancer Inst 96 : — J Clin Endocrinol Metab 80 : — Cancer Chemother Pharmacol 46 : 35 — Crit Rev Oncol Hematol 57 : 53 — Br J Cancer 74 : — Clin Cancer Res 4 : — Oncology 54 Suppl 2 : 19 — Steroids 58 : — Acta Oncol 35 Suppl 5 : 15 — Cancer 80 : — Gan to Kagaku Ryoho 29 : — A phase I study of a new potent oral aromatase inhibitor of breast cancer.

Cancer 75 : — Cancer Res 52 : — Aromasin Study Group. J Clin Oncol 17 : — Clin Cancer Res 3 : — Eur J Cancer 36 : — Br J Cancer 72 : — Arimidex Study Group. Cancer 79 : — Cancer 95 : — Ann Oncol 9 : — Eur J Cancer 39 : — Cancer 92 : — Lancet : 60 — J Clin Oncol 25 : — Ann Oncol 16 : — J Clin Oncol 23 : — N Engl J Med [Errata and ] : — Lancet : — Lancet [Erratum ] : — Lancet Oncol [Erratum ] 7 : — Cancer : — Ann Oncol 13 : — Nabholtz JM , Gligorov J Cardiovascular safety profiles of aromatase inhibitors: a comparative review.

Drug Saf [Erratum 30 : ]— Ellis MJ Neoadjuvant endocrine therapy for breast cancer: more questions than answers. Clin Cancer Res 6 : — Ann Oncol 12 : — J Steroid Biochem Mol Biol 80 : — Trends Endocrinol Metab 16 : — J Natl Cancer Inst 93 : — Apoptosis 8 : 55 — Cancer Res 68 : — Massarweh S , Schiff R Unraveling the mechanisms of endocrine resistance in breast cancer: new therapeutic opportunities.

Clin Cancer Res 13 : — J Steroid Biochem Mol Biol : — Apoptosis 10 : — Sabnis G , Traztizamab increases sensitivity of hormone dependent and hormone refractory breast cancer cells to endocrine agents. In: Schayowitz A, ed. Int J Cancer : — Cancer Res 69 : — Johnston SR Integration of endocrine therapy with targeted agents.

Breast Cancer Res 10 Suppl 4 : S Dodwell D , Wardley A , Johnston S Postmenopausal advanced breast cancer: options for therapy after tamoxifen and aromatase inhibitors. Breast 15 : — Breast Cancer Res Treat : 43 — Breast Cancer Res Treat Supp1 Cristofanilli M , A phase II multicenter, double blind, randomized trial to compare anastrozole plus gefitinib with anastrozole plus placebo in postmenopausal women with hormone receptor positive metastatic breast cancer.

Baselga J Treatment of postmenopausal women with locally advanced or metastatic breast cancer with letrozole alone or in combination with temsirolimus: a randomized, 3 arm phase 2 study. Chow LW Phase 3 study of temsirolimus with letrozole or letrozole alone in postmenopausal women with locally advanced or metastatic breast cancer. Santen RJ Endocrine responsive cancer. Williams Textbook of Endocrinology. Philadelphia : W. Saunders ; — Cancer Lett : — Biochim Biophys Acta : 63 — Liehr JG Genotoxic effects of estrogens.

Mutat Res : — Pasanen M , Pelkonen O Solubilization and partial purification of human placental cytochromes P Arch Biochem Biophys : — Steroids 50 : 11 — Steroids 50 : 37 — Muto N , Tan L Purification of oestrogen synthetase by high-performance liquid chromatography.

Two membrane-bound enzymes from the human placenta. J Chromatogr : — J Mol Endocrinol 8 : 53 — Sign In. Advanced Search. Search Menu. Article Navigation. Close mobile search navigation Article Navigation. Volume Article Contents Abstract. Discovery and Characterization of Aromatase. Early Physiological Studies of Aromatase.

Steroidal Aromatase Inhibitor Development. Nonsteroidal Aromatase Inhibitor Development. This action is done by blocking the aromatase enzyme by turning the hormone, androgen, into small amounts of estrogen.

Aromatase inhibitors are unable to stop ovaries from producing estrogen; therefore, these inhibitors only work in post-menopausal women. Aromatase deficiency is rare in humans; however, if aromatase is nonfunctional due to a mutation, estrogen synthesis cannot occur. Affected females are diagnosed at birth because of the obvious characteristics of pseudohermaphroditism.

During the childhood of these girls, delayed bone maturation can occur along with cystic ovaries. However, affected males are diagnosed later in life because there are not obvious birth defects. Clincal symptoms such as a tall physique, delayed bone maturation, epiphyseal closure, bone pain, and excess adiposy. Research shows a rare disorder caused by excessive aromatase activity that can cause familial gynecomastia and feminization of both sexes. This can be inherited in an autosomal dominant manner, affecting females and males differently.

See human P 19 family in Cytochrome P Sussman , Whitney Smith , Alexander Berchansky. Aromatase From Proteopedia.